ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Update Il y a 4 ans
Reference: NCT02955615

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.


Inclusion criteria

  • Systemic Lupus Erythematosus

Links